Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against ITrypanosoma cruzi/I

• Published in: Pharmaceutics Vol. 15; no. 3
• Main Authors: Pagotti, Mariana C, Dias, Herbert J, Candido, Ana Carolina B. B, Oliveira, Thaís A. S, Borges, Alexandre, Oliveira, Nicoli D, Lopes, Carla D, Orenha, Renato P, Parreira, Renato L. T, Crotti, Antônio E. M, Magalhães, Lizandra G
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.02.2023
• Subjects: Chagas' disease; Drug therapy; Brazil
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15030754

Chagas disease is a neglected tropical disease that affects more than 8 million people. Although there are therapies against this disease, the search for new drugs is important because the current treatments show limited effectiveness and high toxicity. In this work, eighteen dihydrobenzofuran-type neolignans (DBNs) and two benzofuran-type neolignans (BNs) were synthesized and evaluated against amastigote forms of two Trypanosoma cruzi strains. The in vitro cytotoxicity and hemolytic activity of the most active compounds were also evaluated and their relationships with T. cruzi tubulin DBNs were investigated by an in silico approach. Four DBNs demonstrated activity against the T. cruzi Tulahuen lac-Z strain (IC[sub.50] from 7.96 to 21.12 µM), and DBN 1 exhibited the highest activity against the amastigote forms of the T. cruzi Y strain (IC[sub.50] 3.26 μM). Compounds 1–4 showed CC[sub.50] values higher than antitrypanosomal activities, except for DBN 3. All DBNs with antitrypanosomal activity demonstrated CH[sub.50] higher than 100 µM. The in silico results indicated that DBNs 1, 2, and 4 are capable of destabilizing the dynamics of the tubulin-microtubule from the vinca site. These compounds displayed promising in vitro activity against T. cruzi, especially compound 1, and can be considered molecular prototypes for the development of new antiparasitic drugs.